Low testing rates and high BRCA prevalence: Poly (ADP-ribose) polymerase inhibitor use in Middle East BRCA/homologous recombination deficiency-positive cancer patients

Table 1 Demographics and clinical characteristics of germline BRCA-positive and BRCA-negative breast cancer

gBRCA1	Positive	Negative
Total, n (%)	15 (26.3)	42 (73.7)
Age in yr at diagnosis, mean ± SD	42.1 ± 11	45.3 ± 8.7
Positive family history, n (%)	8 (53.3)	16 (38.1)
First-degree relative, n (%)	8 (53.3)	9 (21.3)
Non-first-degree relatives, n (%)	4 (26.6)	11 (26.1)
H/o IVF & Rx, n (%)	0	0
H/o hormone Rx, n (%)	1 (6.6)	4 (9.5)
ECOG PS at diagnosis2, n (%)
0	13 (86.7)	40 (95.2)
1	2 (12.3)	2 (4.8)
Histology at diagnosis, n (%)
Invasive ductal carcinoma	12 (80)	35 (83.3)
Invasive lobular carcinoma	1 (6.6)	4 (9.5)
Grade at diagnosis, mean ± SD	3 ± 0.6	2 ± 0.7
Stage at diagnosis, n (%)
1	1 (6.6)	0
2	7 (46.6)	21 (50)
3	4 (26.6)	13 (31)
4	3 (20)	8 (19)
Categories3, n (%)
HER2-positive	4 (26.6)	12 (28.7)
Triple-negative	3 (20)	8 (19.0)
HR-positive and HER2-negative	6 (40)	15 (35.7)
HR-positive and HER2-positive	3 (20)	6 (14.3)

¹Includes BRCA1 and BRCA2.

²Eastern Cooperative Oncology Group Performance Status.

³Categories of breast cancer having prognostic significance.

ECOG PS: Eastern Cooperative Oncology Group Performance Status; HER2: Human epidermal growth factor receptor 2; HR: Homologous recombination; IVF: In vitro fertilization; Rx: Medical prescription.